Philip Home spends much of his time researching Internal medicine, Diabetes mellitus, Endocrinology, Insulin and Type 2 diabetes. Internal medicine is closely attributed to Surgery in his work. His biological study spans a wide range of topics, including Anesthesia, Heart failure, Transplantation and Intensive care medicine.
His work deals with themes such as Pharmacokinetics and Crossover study, which intersect with Endocrinology. The concepts of his Type 2 diabetes study are interwoven with issues in Gastroenterology, Alternative medicine, Clinical endpoint, Rosiglitazone and Glycemic. Philip Home interconnects Morning and Insulin lispro in the investigation of issues within Insulin glargine.
His scientific interests lie mostly in Internal medicine, Diabetes mellitus, Endocrinology, Insulin and Type 2 diabetes. His research on Internal medicine often connects related areas such as Type 1 diabetes. His studies in Diabetes mellitus integrate themes in fields like Surgery, Gerontology, Family medicine and Intensive care medicine.
His work on NPH insulin, Pancreatic hormone and Metabolism as part of his general Endocrinology study is frequently connected to Evening, thereby bridging the divide between different branches of science. His Insulin research integrates issues from Meal and Glucose control. He mostly deals with Insulin detemir in his studies of Type 2 diabetes.
Philip Home focuses on Internal medicine, Type 2 diabetes, Diabetes mellitus, Insulin and Endocrinology. His Internal medicine study frequently draws connections between adjacent fields such as Basal insulin. His Type 2 diabetes study combines topics from a wide range of disciplines, such as Gastroenterology and Pediatrics.
His work carried out in the field of Diabetes mellitus brings together such families of science as Observational study, Gerontology, MEDLINE and Intensive care medicine. The Insulin study combines topics in areas such as Weight gain, Glucagon-like peptide 1 receptor and Bioinformatics. His Endocrinology research incorporates themes from Non interventional and Pharmacodynamics.
His primary areas of study are Internal medicine, Diabetes mellitus, Type 2 diabetes, Insulin and Endocrinology. His study on Internal medicine is mostly dedicated to connecting different topics, such as Placebo. He has researched Diabetes mellitus in several fields, including MEDLINE and Intensive care medicine.
His Type 2 diabetes study incorporates themes from Alternative medicine, Surgery, Disease and Specialty. His study in Endocrinology is interdisciplinary in nature, drawing from both Animal data, Malignancy and Bioinformatics. Philip Home has included themes like Insulin glulisine, Postprandial, Insulin aspart and Insulin lispro in his Pharmacodynamics study.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
R C Turner;R R Holman;C A Cull;I M Stratton.
The Lancet (1998)
European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice.
Guy De Backer;Ettore Ambrosioni;Knut Borch-Johnsen;Carlos Brotons.
European Heart Journal (2003)
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial
Philip D. Home;Stuart J. Pocock;Henning Beck-Nielsen;Paula S. Curtis.
The Lancet (2009)
2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASDThe Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD)
Francesco Cosentino;Peter J Grant;Victor Aboyans;Clifford J Bailey.
European Heart Journal (2020)
Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis.
Philip D. Home;Stuart J. Pocock;Henning Beck-Nielsen;Ramón Gomis.
The New England Journal of Medicine (2007)
A desktop guide to Type 2 diabetes mellitus
M. Aguilar;K. G.M.M. Alberti;S. A. Amiel;J. Azzopardi.
Diabetic Medicine (1999)
A 26-Week, Randomized, Parallel, Treat-to-Target Trial Comparing Insulin Detemir With NPH Insulin as Add-On Therapy to Oral Glucose-Lowering Drugs in Insulin-Naïve People With Type 2 Diabetes
Kjeld Hermansen;Melanie Davies;Taudeusz Derezinski;Gabrielle Martinez Ravn.
Diabetes Care (2006)
A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes
J. Rosenstock;M. Davies;P. D. Home;J. Larsen.
Principles for National and Regional Guidelines on Cardiovascular Disease Prevention A Scientific Statement From the World Heart and Stroke Forum
Sidney C. Smith;Rod Jackson;Thomas A. Pearson;Valentin Fuster.
The Role of Asymmetric Dimethylarginine (ADMA) in Endothelial Dysfunction and Cardiovascular Disease
Latika Sibal;Sharad C Agarwal;Philip D Home;Rainer H Boger.
Current Cardiology Reviews (2010)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: